| 產(chǎn)品編號(hào) | bs-4741R |
| 英文名稱 | Rabbit Anti-APOC3 antibody |
| 中文名稱 | 載脂蛋白C3抗體 |
| 別 名 | APO C3; Apo CIII; Apo-CIII; APOC 3; ApoC III; ApoC-III; APOC3; APOC3_HUMAN; ApoCIII; Apolipoprotein C III; Apolipoprotein C-III; Apolipoprotein C3; ApolipoproteinCIII; MGC150353. |
 |
Specific References (4) | bs-4741R has been referenced in 4 publications.
[IF=4.87] Lozhkin, Andrey, et al. "NADPH oxidase 4 regulates vascular inflammation in aging and atherosclerosis." Journal of Molecular and Cellular Cardiology (2016). IHC-F ; Mouse.
[IF=2.984] Yitong Pan. et al. N-acetyl-L-tryptophan attenuates hepatic ischemia-reperfusion injury via regulating TLR4/NLRP3 signaling pathway in rats. Peerj. 2021 Aug;9:e11909 WB,IF ; Rat.
[IF=2.136] Hou Z et al. Comparative proteomic identification buffalo spermatozoa during in vitro capacitation. (2018) Theriogenology 126:303-309. WB ; Buffalo.
[IF=2.136] Hou Z et al. Comparative proteomic identification of capacitation and noncapacitation swamp buffalo spermatozoa. Theriogenology. 2019 Feb 7;128:176-183. WB ; buffalo.
|
| 研究領(lǐng)域 | 腫瘤 心血管 細(xì)胞生物 免疫學(xué) 信號(hào)轉(zhuǎn)導(dǎo) 脂蛋白 新陳代謝 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | (predicted: Human,Cow) |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,ICC/IF=1:100-500,IF=1:100-500,ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 9kDa |
| 細(xì)胞定位 | 分泌型蛋白 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human APOC3: 21-80/99 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
Apolipoprotein C-III is a very low density lipoprotein (VLDL) protein. It inhibits lipoprotein lipase and hepatic lipase and it is thought to delay catabolism of triglyceride-rich particles. An increase in apoC-III levels induces the development of hypertriglyceridemia. Function: Inhibits lipoprotein lipase and hepatic lipase and decreases the uptake of lymph chylomicrons by hepatic cells. This suggests that it delays the catabolism of triglyceride-rich particles. Subcellular Location: Secreted. Tissue Specificity: Constitutes 50% of the protein fraction of VLDL and 2% of that of HDL. Synthesized predominantly in liver and to a lesser degree in intestine. Post-translational modifications: O-linked glycan consists of Gal-GalNAc disaccharide, further modified with up to 3 sialic acid residues. O-glycosylated on Thr-94 with a core 1 or possibly core 8 glycan. DISEASE: Hyperalphalipoproteinemia 2 (HALP2) [MIM:614028]: A condition characterized by high levels of high density lipoprotein (HDL) and increased HDL cholesterol levels. Note=The disease is caused by mutations affecting the gene represented in this entry. Similarity: Belongs to the apolipoprotein C3 family. SWISS: P02656 Gene ID: 345 Database links: Entrez Gene: 345 Human Entrez Gene: 11814 Mouse Omim: 107720 Human SwissProt: P02656 Human SwissProt: P33622 Mouse Unigene: 73849 Human Unigene: 390161 Mouse Unigene: 195323 Rat |
